UBS Adjusts IDEXX Laboratories Price Target to $627 From $670
UBS has lowered its price target for IDEXX Laboratories, Inc. while maintaining a Neutral rating on the stock.
Stocks · News reference
UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $627
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Europe Companion Animal Diagnostics Market Size and Forecast, 2021 - 2031 | AI-Enabled Testing and Preventive Pet Care Fuel 9.5% CAGR and a US$2.27 Billion Opportunity
Europe's companion animal diagnostics market is projected to reach US$2.27 billion by 2031, growing at a 9.5% CAGR from 2024-2031. Growth is driven by AI-enabled testing, preventive pet care adoption, technological advancements, and rising pet insurance uptake. Germany and the UK lead the market, with veterinary hospitals and clinics as the largest end-user segment. Key players are investing in product development and AI integration to enhance diagnostic capabilities.
JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $750
JP Morgan analyst Chris Schott maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $775 to $750.